Mannose-Binding Lectin: Biologic Characteristics and Role in the Susceptibility to Infections and Ischemia-Reperfusion Related Injury in Critically Ill Neonates

Journal of Immunology Research

Volumn 2017, Issue , 2017, Pages

  Auriti, Cinzia ^a   Prencipe, Giusi ^a   Moriondo, Maria ^b   Bersani, Iliana ^a   Bertaina, Chiara ^a   Mondì, Vito ^a   Inglese, Rita ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN;

BIOLOGICAL ACTIVITY; CRITICALLY ILL PATIENT; DNA POLYMORPHISM; GENETIC ANALYSIS; GENETICS; HUMAN; INFECTION SENSITIVITY; NEWBORN DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PERINATAL PERIOD; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; BLOOD; CRITICAL ILLNESS; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; NECROTIZING ENTEROCOLITIS; NEWBORN; PHYSIOLOGY; PREMATURITY;

CRITICAL ILLNESS; DISEASE SUSCEPTIBILITY; ENTEROCOLITIS, NECROTIZING; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; INFANT, PREMATURE; MANNOSE-BINDING LECTIN; POLYMORPHISM, GENETIC; REPERFUSION INJURY;

EID: 85012113426     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2017/7045630     Document Type: Review

References (118)

1. D. C. Kilpatrick, "Mannan-binding lectin: clinical significance and applications," Biochimica et Biophysica Acta, vol. 1572, no. 2-3, pp. 401-413, 2002.
2. M. Sumiya, M. Super, P. Tabona et al., "Molecular basis of opsonic defect in immunodeficient children," The Lancet, vol. 337, no. 8757, pp. 1569-1570, 1991.
3. M. Scorza, R. Liguori, A. Elce, F. Salvatore, and G. Castaldo, "Biological role of mannose binding lectin: from newborns to centenarians," Clinica Chimica Acta, vol. 451, pp. 78-81, 2015.
4. L. J. Schlapbach, M. Mattmann, S. Thiel et al., "Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis," Clinical Infectious Diseases, vol. 51, no. 2, pp. 153-162, 2010.
5. J. P. Zanetta, "Mannose-binding lectins in cerebrum development," Progress inMolecular and Subcellular Biology, vol. 32, pp. 75-96, 2003.
6. F. De Benedetti, C. Auriti, L. E. D'Urbano et al., "Low serum levels of mannose binding lectin are a risk factor for neonatal sepsis," Pediatric Research, vol. 61, no. 3, pp. 325-328, 2007.
7. C. Auriti, G. Prencipe, R. Inglese et al., "Role of mannosebinding lectin in nosocomial sepsis in critically ill neonates," Human Immunology, vol. 71, no. 11, pp. 1084-1088, 2010.
8. C. Auriti, G. Prencipe, B. Caravale et al., "MBL2 gene polymorphisms increase the risk of adverse neurological outcome in preterm infants: a preliminary prospective study," Pediatric Research, vol. 76, no. 5, pp. 464-469, 2014.
9. G. Prencipe, C. Azzari, M. Moriondo et al., "Association between mannose-binding lectin gene polymorphisms and necrotizing enterocolitis in preterminfants," Journal of Pediatric Gastroenterology and Nutrition, vol. 55, no. 2, pp. 160-165, 2012.
10. M. W. Turner, "Mannose-binding lectin (MBL) in health and disease," Immunobiology, vol. 199, no. 2, pp. 327-339, 1998.
11. T. Kawasaki, "Structure and biology of mannan-binding protein, MBP, an important component of innate immunity," Biochimica et Biophysica Acta, vol. 1473, no. 1, pp. 186-195, 1999.
12. D. C. Kilpatrick, "Introduction to mannan-binding lectin," Biochemical Society Transactions, vol. 31, no. 4, pp. 745-747, 2003.
13. N. J. Klein, "Mannose-binding lectin: do we need it?"Molecular Immunology, vol. 42, no. 8, pp. 919-924, 2005.
14. D. L. Worthley, P. G. Bardy, and C. G. Mullighan, "Mannosebinding lectin: biology and clinical implications," Internal Medicine Journal, vol. 35, no. 9, pp. 548-555, 2005.
15. D. P. Eisen and R.M.Minchinton, "Impact ofmannose-binding lectin on susceptibility to infectious diseases," Clinical Infectious Diseases, vol. 37, no. 11, pp. 1496-1505, 2003.
16. K.Takahashi,W.K.E. Ip, I. C.Michelow, andR. A. B. Ezekowitz, "The mannose-binding lectin: a prototypic pattern recognition molecule," CurrentOpinion in Immunology, vol. 18,no. 1, pp. 16-23, 2006.
17. K. Mori, T. Kawasaki, and I. Yamashina, "Subcellular distribution of the mannan-binding protein and its endogenous inhibitors in rat liver," Archives of Biochemistry and Biophysics, vol. 232, no. 1, pp. 223-233, 1984.
18. J.Wild,D. Robinson, and B.Winchester, "Isolation of mannosebinding proteins from human and rat liver," Biochemical Journal, vol. 210, no. 1, pp. 167-174, 1983.
19. L. H. Bouwman, A. Roos, O. T. Terpstra et al., "Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation," Gastroenterology, vol. 129, no. 2, pp. 408-414, 2005.
20. C.D.Collard,R.Lekowski, J. E. Jordan,A.Agah, andG.L. Stahl, "Complement activation following oxidative stress," Molecular Immunology, vol. 36, no. 13-14, pp. 941-948, 1999.
21. C. D. Collard, A. Vakeva, M. A. Morrissey et al., "Complement activation after oxidative stress: role of the lectin complement pathway," American Journal of Pathology, vol. 156, no. 5, pp. 1549-1556, 2000.
22. R.Malhotra, A. C. Willis, A. Lopez Bernal, S. Thiel, and R. B. Sim, "Mannan-binding protein levels in human amniotic fluid during gestation and its interaction with collectin receptor from amnion cells," Immunology, vol. 82, no. 3, pp. 439-444, 1994.
23. P. Garred, K. Brygge, C. H. Sorensen et al., "Mannan binding protein levels in plasma and upper airway secretions and frequency of genotypes in children with recurrence of otitis media," Clinical & Experimental Immunology, vol. 94, no. 1, pp. 99-104, 1993.
24. S. S. Bohlson, S. D. O'Conner, H. J. Hulsebus, M.-M. Ho, and D. A. Fraser, "Complement, C1Q, and C1q-related molecules regulate macrophage polarization," Frontiers in Immunology, vol. 5, article no. 402, 2014.
25. D. A. Fraser andA. J. Tenner, "Directing an appropriateimmune response: the role of defense collagens and other soluble pattern recognition molecules," Current Drug Targets, vol. 9, no. 2, pp. 113-122, 2008.
26. J.Nadesalingam, A. W. Dodds, K. B. M. Reid, and N. Palaniyar, "Mannose-binding lectin recognizes peptidoglycan via the Nacetyl glucosamine moiety, and inhibits ligand-induced proinflammatory effect and promotes chemokine production by macrophages," The Journal of Immunology, vol. 175, no. 3, pp. 1785-1794, 2005.
27. J.-L. Casanova and L. Abel, "Human mannose-binding lectin in immunity: friend, foe, or both?" Journal of Experimental Medicine, vol. 199, no. 10, pp. 1295-1299, 2004.
28. A. S. Grumach, M. E. Ceccon, R. Rutz, A. Fertig, and M. Kirschfink, "Complement profile in neonates of different gestational ages," Scandinavian Journal of Immunology, vol. 79, no. 4, pp. 276-281, 2014.
29. O. Neth, D. L. Jack, M. Johnson, N. J. Klein, and M.W. Turner, "Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannosebinding lectin-associated serine protease after binding to Staphylococcus aureus," Journal of Immunology, vol. 169, no. 8, pp. 4430-4436, 2002.
30. S.Thiel, T. Vorup-Jensen, C. M. Stover et al., "A second serine protease associated with mannan-binding lectin that activates complement," Nature, vol. 386, no. 6624, pp. 506-510, 1997.
31. M.Matsushita and T. Fujita, "Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease," The Journal of Experimental Medicine, vol. 176, no. 6, pp. 1497-1502, 1992.
32. M. Matsushita and T. Fujita, "Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation," Immunobiology, vol. 194, no. 4-5, pp. 443-448, 1995.
33. M. R. Dahl, S. Thiel, M. Matsushita et al., "MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway," Immunity, vol. 15, no. 1, pp. 127-135, 2001.
34. S. E. Degn, L. Jensen, A. G. Hansen et al., "Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum whereas neither MASP-1 nor MASP-3 is required for alternative pathway function," Journal of Immunology, vol. 189, no. 8, pp. 3957-3969, 2012.
35. Y. Liu, Y. Endo, D. Iwaki et al., "Human M-ficolin is a secretory protein that activates the lectin complement pathway," Journal of Immunology, vol. 175, no. 5, pp. 3150-3156, 2005.
36. M. Matsushita, Y. Endo, and T. Fujita, "Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease," Journal of Immunology, vol. 164, no. 5, pp. 2281-2284, 2000.
37. M.Matsushita,M. Kuraya, N. Hamasaki,M. Tsujimura, H. Shiraki, andT. Fujita, "Activation of the lectin complement pathway by H-ficolin (Hakata antigen)," The Journal of Immunology, vol. 168, no. 7, pp. 3502-3506, 2002.
38. M. Zhang, K. Takahashi, E. M. Alicot et al., "Activation of the lectin pathway by natural IgM in a model of ischemia/ reperfusion injury," The Journal of Immunology, vol. 177, no. 7, pp. 4727-4734, 2006.
39. M. Kuraya, M. Matsushita, Y. Endo, S. Thiel, and T. Fujita, "Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G," International Immunology, vol. 15, no. 1, pp. 109-117, 2003.
40. H. Morio, H. Kurata, R. Katsuyama, S. Oka, Y. Kozutsumi, and T. Kawasaki, "Renal expression of serum-type mannan-binding protein in rat," European Journal of Biochemistry, vol. 243, no. 3, pp. 770-774, 1997.
41. T. Vorup-Jensen, E. S. Sørensen, U. B. Jensen et al., "Recombinant expression of human mannan-binding lectin," International Immunopharmacology, vol. 1, no. 4, pp. 677-687, 2001.
42. S.Wagner, N. J. Lynch,W.Walter,W. J. Schwaeble, andM. Loos, "Differential expression of themurinemannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues," The Journal of Immunology, vol. 170, no. 3, pp. 1462-1465, 2003.
43. D.L.Grasso, L. Segat, E. Zocconi, O. Radillo,C.Trevisiol, and S. Crovella, "MBL expression inpatientswith recurrent tonsillitis," International Journal of Pediatric Otorhinolaryngology, vol. 73, no. 11, pp. 1550-1553, 2009.
44. J. Seyfarth, P. Garred, and H. O. Madsen, "Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes," Molecular Immunology, vol. 43, no. 7, pp. 962-971, 2006.
45. O. Babula, G. Lazdane, J. Kroica, W. J. Ledger, and S. S. Witkin, "Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannosebinding lectin gene polymorphism in latvian women," Clinical Infectious Diseases, vol. 37, no. 5, pp. 733-737, 2003.
46. S. V. Petersen, S. Thiel, and J. C. Jensenius, "The mannanbinding lectin pathway of complement activation: biology and disease association,"Molecular Immunology, vol. 38, no. 2-3, pp. 133-149, 2001.
47. G. Ambrus, P. Gál, M. Kojima et al., "Natural substrates and inhibitors ofmannan-binding lectin-associated serine protease-1 and-2: a study on recombinant catalytic fragments," Journal of Immunology, vol. 170, no. 3, pp. 1374-1382, 2003.
48. M. E. Taylor, P. M. Brickell, R. K. Craig, and J. A. Summerfield, "Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein," Biochemical Journal, vol. 262, no. 3, pp. 763-771, 1989.
49. K. Sastry, G. A. Herman, L. Day et al., "The human mannosebinding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10," Journal of Experimental Medicine, vol. 170, no. 4, pp. 1175-1189, 1989.
50. P. Garred, F. Larsen, H. O. Madsen, and C. Koch, "Mannosebinding lectin deficiency-revisited," Molecular Immunology, vol. 40, no. 2-4, pp. 73-84, 2003.
51. H. O. Madsen, P. Garred, S. Thiel et al., "Interplay between promoter and structural gene variants control basal serumlevel of mannan-binding protein," The Journal of Immunology, vol. 155, no. 6, pp. 3013-3020, 1995.
52. H.O.Madsen, P.Garred, J. A. L.Kurtzhals et al., "Anewfrequent allele is the missing link in the structural polymorphism of the human mannan-binding protein," Immunogenetics, vol. 40, no. 1, pp. 37-44, 1994.
53. R. J. Lipscombe, M. Sumiya,A.V. S.Hill et al., "High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene," Human Molecular Genetics, vol. 1, no. 9, pp. 709-715, 1992.
54. R. Steffensen, S. Thiel, K. Varming, C. Jersild, and J. C. Jensenius, "Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers," Journal of Immunological Methods, vol. 241, no. 1-2, pp. 33-42, 2000.
55. G. L. Sorensen, I. Petersen, S. Thiel et al., "Genetic influences on Mannan-binding lectin (MBL) and Mannan-binding lectin associated serine protease-2 (MASP-2) activity," Genetic Epidemiology, vol. 31, no. 1, pp. 31-41, 2007.
56. M. Matsushita, S. Thiel, J. C. Jensenius, I. Terai, and T. Fujita, "Proteolytic activities of two types of mannose-binding lectinassociated serine protease," The Journal of Immunology, vol. 165, no. 5, pp. 2637-2642, 2000.
57. C. A. Farrar, E. Asgari,W. J. Schwaeble, and S. H. Sacks, "Which pathways trigger the role of complement in ischaemia/ reperfusion injury?" Frontiers in Immunology, vol. 19, no. 3, p. 341, 2012.
58. M. Zhang, K. Takahashi, E. M. Alicot et al., "Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury," Journal of Immunology, vol. 177, no. 7, pp. 4727-4734, 2006.
59. J. E. Jordan, M. C. Montalto, and G. L. Stahl, "Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury," Circulation, vol. 104, no. 12, pp. 1413-1418, 2001.
60. M. L. Hart, K. A. Ceonzo, L. A. Shaffer et al., "Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q," Journal of Immunology, vol. 174, no. 10, pp. 6373-6380, 2005.
61. B. De Vries, S. J. Walter, C. J. Peutz-Kootstra, T. G. A. M. Wolfs, L.W. E. VanHeurn, andW. A. Buurman, "Themannosebinding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury," American Journal of Pathology, vol. 165, no. 5, pp. 1677-1688, 2004.
62. R. Gesuete, C. Storini, A. Fantin et al., "Recombinant C1 inhibitor in brain ischemic injury," Annals of Neurology, vol. 66, no. 3, pp. 332-342, 2009.
63. Y. L. Lau, S. Y. Chan, M. W. Turner, J. Fong, and J. Karlberg, "Mannose-binding protein in preterm infants: developmental profile and clinical significance," Clinical and Experimental Immunology, vol. 102, no. 3, pp. 649-654, 1995.
64. M. M. Dean, R. M. Minchinton, S. Heatley, and D. P. Eisen, "Mannose binding lectin acute phase activity in patients with severe infection," Journal of Clinical Immunology, vol. 25, no. 4, pp. 346-352, 2005.
65. D. P. Eisen, M. M. Dean, M. A. Boermeester et al., "Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection," Clinical Infectious Diseases, vol. 47, no. 4, pp. 510-516, 2008.
66. D. P. Eisen, M. M. Dean, P. Thomas et al., "Low mannosebinding lectin function is associated with sepsis in adult patients," FEMS Immunology andMedicalMicrobiology, vol. 48, no. 2, pp. 274-282, 2006.
67. G. De Pascale, S. L. Cutuli, M. A. Pennisi, and M. Antonelli, "The role of mannose-binding lectin in severe sepsis and septic shock,"Mediators of Inflammation, vol. 2013, Article ID 625803, 8 pages, 2013.
68. L. P. Gravina, C. Crespo, H. Giugno et al., "Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients," Journal of Cystic Fibrosis, vol. 14, no. 1, pp. 78-83, 2015.
69. P. Garred, T. Pressler, H. O. Madsen et al., "Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis," Journal of Clinical Investigation, vol. 104, no. 4, pp. 431-437, 1999.
70. O. Neth, I. Hann, M. W. Turner, and N. J. Klein, "Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study," The Lancet, vol. 358, no. 9282, pp. 614-618, 2001.
71. N. A. Peterslund, C. Koch, J. C. Jensenius, and S. Thiel, "Association between deficiency of mannose-binding lectin and severe infections after chemotherapy," Lancet, vol. 358, no. 9282, pp. 637-638, 2001.
72. J. D. Chalmers, G. B. Fleming, A. T. Hill, and D. C. Kilpatrick, "Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis," Glycobiology, vol. 21, no. 3, pp. 271-282, 2011.
73. A. Moreto, C. Fariñas-Alvarez, M. Puente et al., "Mannosebinding lectin gene variants and infections in patients receiving autologous stemcell transplantation," BMC Immunology, vol. 15, no. 1, article 17, 2014.
74. Q.-Q. Wan, Q.-F. Ye, and J.-D. Zhou, "Mannose-binding lectin 2 and ficolin-2 gene polymorphisms influence the susceptibility to bloodstream infections in kidney transplant recipients," Transplantation Proceedings, vol. 45, no. 9, pp. 3289-3292, 2013.
75. H. L. Stevenson, A. Amador, J.McCue et al., "Mannose binding lectin (mbl2) haplotype frequencies in solid organ transplant patients and correlation withMBL protein levels-evaluation of complement-mediated effector pathway deficiency," Transplant Immunology, vol. 28, no. 2-3, pp. 73-80, 2013.
76. J. Damman and M. A. Seelen, "Mannan binding lectin: a twofaced regulator of renal allograft injury?" Kidney International, vol. 83, no. 2, pp. 191-193, 2013.
77. S. J. Budd, R. M. Aris, A. A. Medaiyese, S. L. Tilley, and I. P. Neuringer, "Increased plasma mannose binding lectin levels are associated with bronchiolitis obliterans after lung transplantation," Respiratory Research, vol. 13, article no. 56, 2012.
78. V. Pradhan, P. Surve, and K. Ghosh, "Mannose binding lectin (MBL) in autoimmunity and its role in systemic lupus erythematosus (SLE)," Journal of Association of Physicians of India, vol. 58, no. 11, pp. 688-690, 2010.
79. D. Golshayan, A. Wójtowicz, S. Bibert et al., "Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation," Kidney International, vol. 89, no. 4, pp. 927-938, 2016.
80. D. Eurich, S. Boas-Knoop, A. Yahyazadeh et al., "Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease," Transplant Infectious Disease, vol. 14, no. 5, pp. 488-495, 2012.
81. M. Ibernon, F. Moreso, and D. Serón, "Subclinical rejection in renal transplants is associated with low serum mannosebinding lectin levels," Kidney International Supplements, vol. 1, no. 2, pp. 36-39, 2011.
82. K. E. Carroll, M. M. Dean, S. L. Heatley et al., "High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation," Transplantation, vol. 91, no. 9, pp. 1044-1049, 2011.
83. J. E. Fildes, S. M. Shaw, A. H. Walker et al., "Mannosebinding lectin deficiency offers protection from acute graft rejection after heart transplantation," Journal of Heart and Lung Transplantation, vol. 27, no. 12, pp. 1353-1356, 2008.
84. A. E. Fiane, T. Ueland, S. Simonsen et al., "Low mannosebinding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation," European Heart Journal, vol. 26, no. 16, pp. 1660-1665, 2005.
85. S.-Q. Zhao and Z. Hu, "Mannose-binding lectin and diabetic nephropathy in type 1 diabetes," Journal of Clinical Laboratory Analysis, vol. 30, no. 4, pp. 345-350, 2016.
86. L.-Z. Guan, Q. Tong, and J. Xu, "Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes," PLoS ONE, vol. 10, no. 3, Article IDe0119699, 2015.
87. N. Zhang, M. Zhuang, A. Ma et al., "Association of levels of Mannose-binding lectin and the MBL2genewith type 2 diabetes and diabetic nephropathy," PLoS ONE, vol. 8, no. 12, Article ID e83059, 2013.
88. T. K. Hansen, C. Forsblom, M. Saraheimo et al., "Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes," Diabetologia, vol. 53, no. 7, pp. 1517-1524, 2010.
89. M. Saraheimo, C. Forsblom, T. K. Hansen et al., "Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy," Diabetologia, vol. 48,no. 1, pp. 198-202, 2005.
90. A. S. Swierzko,M. A. Bart?omiejczyk, A. Brzostek et al., "Mycobacterial antigen 85 complex (Ag85) as a target for ficolins and mannose-binding lectin," International Journal of Medical Microbiology, vol. 306, no. 4, pp. 212-221, 2016.
91. M. A. Bartlomiejczyk, A. S. Swierzko, A. Brzostek, J. Dziadek, and M. Cedzynski, "Interaction of lectin pathway of complement-activating pattern recognition molecules with Mycobacteria," Clinical and Experimental Immunology, vol. 178, no. 2, pp. 310-319, 2014.
92. N. Singla, D. Gupta, A. Joshi, N. Batra, J. Singh, andN. Birbian, "Association of mannose-binding lectin gene polymorphism with tuberculosis susceptibility and sputum conversion time," International Journal of Immunogenetics, vol. 39, no. 1, pp. 10-14, 2012.
93. C. Søborg, H. O. Madsen, ? A. B. Andersen, T. Lillebaek, A. Kok-Jensen, and P. Garred, "Mannose-binding lectin polymorphisms in clinical tuberculosis," Journal of Infectious Diseases, vol. 188, no. 5, pp. 777-782, 2003.
94. A. Mishra, J. S. Antony, P. Gai et al., "Mannose-binding Lectin (MBL) as a susceptible host factor influencing Indian Visceral Leishmaniasis," Parasitology International, vol. 64, no. 6, pp. 591-596, 2015.
95. F. J. De Araujo, T. G. Mesquita, L. D. O. Da Silva et al., "Functional variations in MBL2gene are associated with cutaneous leishmaniasis in the Amazonas state of Brazil," Genes and Immunity, vol. 16, no. 4, pp. 284-288, 2015.
96. M. Asgharzadeh, A.Mazloumi,H. S. Kafil, and A. Ghazanchaei, "Mannose-binding lectin gene and promoter polymorphism in visceral leishmaniasis caused by Leishmania infantum," Pakistan Journal of Biological Sciences, vol. 10, no. 11, pp. 1850-1854, 2007.
97. D. P.Alonso, A. F. B. Ferreira, P. E.M.Ribolla et al., "Genotypes of themannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications," Journal of Infectious Diseases, vol. 195, no. 8, pp. 1212-1217, 2007.
98. A. R. Ambrosio and I. J. T. De Messias-Reason, "Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism," Parasite Immunology, vol. 27, no. 9, pp. 333-340, 2005.
99. I. K. F. De Miranda Santos, C. H. N. Costa, H. Krieger et al., "Mannan-binding lectin enhances susceptibility to visceral leishmaniasis," Infection and Immunity, vol. 69, no. 8, pp. 5212-5215, 2001.
100. M. Matsushita, H.Miyakawa, A. Tanaka et al., "Single nucleotide polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis," Journal of Autoimmunity, vol. 17, no. 3, pp. 251-257, 2001.
101. L. H. Bouwman, B. O. Roep, and A. Roos, "Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity," Human Immunology, vol. 67, no. 4-5, pp. 247-256, 2006.
102. K. J. Fidler, P. Wilson, J. C. Davies, M. W. Turner, M. J. Peters, and N. J. Klein, "Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin," Intensive CareMedicine, vol. 30,no. 7, pp. 1438-1445, 2004.
103. A. C. Gordon, U. Waheed, T. K. Hansen et al., "Mannosebinding lectin polymorphisms in severe sepsis: relationship to levels, incidence, and outcome," Shock, vol. 25, no. 1, pp. 88-93, 2006.
104. R. C. M. Stephens, K. Fidler, P.Wilson et al., "Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children," Intensive Care Medicine, vol. 32, no. 2, pp. 286-294, 2006.
105. A. B. Dzwonek, O.W. Neth,R.Thiébaut et al., "The role ofmannose-binding lectin in susceptibility to infection in preterm neonates," Pediatric Research, vol. 63, no. 6, pp. 680-685, 2008.
106. O. A. Koroglu, H. Onay, G. Erdemir et al., "Mannose-binding lectin gene polymorphism and early neonatal outcome in preterm infants," Neonatology, vol. 98, no. 4, pp. 305-312, 2010.
107. J. Israëls, F.N. J. Frakking, L. C. M. Kremer,M.Offringa, T.W. Kuijpers, and M.D. VanDeWetering, "Mannose-binding lectin and infection risk in newborns: a systematic review," Archives of Disease in Childhood: Fetal and Neonatal Edition, vol. 95, no. 6, pp. F452-F461, 2010.
108. W. A. Wahab Mohamed and M. A. Saeed, "Mannose-binding lectin serum levels in neonatal sepsis and septic shock," Journal ofMaternal-Fetal and NeonatalMedicine, vol. 25, no. 4, pp. 411-414, 2012.
109. A. St Swierzko, A. Szala, M. Cedzynski et al., "Mannan-binding lectin genotypes and genotype-phenotype relationships in a large cohort of Polish neonates," Human Immunology, vol. 70, no. 1, pp. 68-72, 2009.
110. L. J. Schlapbach, P. Latzin,N. Regamey et al., "Mannose-binding lectin cord blood levels and respiratory symptoms during infancy: a prospective birth cohort study," Pediatric Allergy and Immunology, vol. 20, no. 3, pp. 219-226, 2009.
111. A. S. Swierzko, M. Cedzynski, I. Domzalska-Popadiuk et al., "Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associations," Molecular Immunology, vol. 46, no. 8-9, pp. 1696-1701, 2009.
112. A.-M. J. Oudshoorn, F. A. M. van den Dungen, K. P. Bach et al., "Mannose-binding lectin in term newborns and their mothers: genotypic and phenotypic relationship," Human Immunology, vol. 69, no. 6, pp. 344-348, 2008.
113. M.-A. Dommergues, J. Patkai, J.-C. Renauld, P. Evrard, and P. Gressens, "Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium," Annals of Neurology, vol. 47, no. 1, pp. 54-63, 2000.
114. J. Patkai, B. Mesples, M.-A. Dommergues et al., "Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain," Pediatric Research, vol. 50, no. 2, pp. 222-230, 2001.
115. K. B. Nelson, J. M. Dambrosia, J. K. Grether, and T.M. Phillips, "Neonatal cytokines and coagulation factors in children with cerebral palsy," Annals of Neurology, vol. 44, no. 4, pp. 665-675, 1998.
116. P. H. Yager, Z. You, T. Qin et al., "Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice," Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 5, pp. 1030-1039, 2008.
117. A. Cervera, A. M. Planas, C. Justicia et al., "Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke," PLoS ONE, vol. 5, no. 2,Article ID e8433, 2010.
118. D. C. Kilpatrick, "Consensus statement on the future of mannan-binding lectin (MBL)-replacement therapy," Biochemical Society Transactions, vol. 31, no. 4, p. 776, 2003.